Active substance teclistamab
Holder     Janssen-Cilag NV
Status Closed
Indication monotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior lines of therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and who have exhausted all commercially approved and clinically appropriate treatment options, are ineligible for a clinical trial and have evidence of disease progression after the last therapy
Public documents Approbation
  Approbation amendement
  Information for the patient
  Informed consent
Last update 05/09/2023


Last updated on 23/04/2024